Market Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Sanofi and Regeneron Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol

[PR Newswire] – PARIS AND TARRYTOWN, N.Y., Nov. 19, 2014 /PRNewswire/ — Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new detailed positive results from six Phase 3 ODYSSEY trials that showed . . . → Read More: Market Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Sanofi and Regeneron Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol Similar Articles: Stock Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Regeneron cuts top end of eye drug sales forecast Market Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Regeneron Announces Upcoming 2014 Investor Conference Presentations Stock Update (NASDAQ:REGN): EYLEA® (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.